126 related articles for article (PubMed ID: 38578828)
21. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
[TBL] [Abstract][Full Text] [Related]
22.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
23. Analysis of Antitumor Effects of CAR-T Cells in Mice with Solid Tumors.
Rodriguez-Garcia A; Watanabe K; Guedan S
Methods Mol Biol; 2020; 2086():251-271. PubMed ID: 31707682
[TBL] [Abstract][Full Text] [Related]
24. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
25. Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib.
Qin JS; Johnstone TG; Baturevych A; Hause RJ; Ragan SP; Clouser CR; Jones JC; Ponce R; Krejsa CM; Salmon RA; Ports MO
J Immunother; 2020 May; 43(4):107-120. PubMed ID: 31899702
[TBL] [Abstract][Full Text] [Related]
26. Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia.
Wen J; Chen Y; Yang J; Dai C; Yu S; Zhong W; Liu L; He C; Zhang W; Yang T; Liu L; Hu J
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37524506
[TBL] [Abstract][Full Text] [Related]
27. CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.
Boucher JC; Li G; Kotani H; Cabral ML; Morrissey D; Lee SB; Spitler K; Beatty NJ; Cervantes EV; Shrestha B; Yu B; Kazi A; Wang X; Sebti SM; Davila ML
Cancer Immunol Res; 2021 Jan; 9(1):62-74. PubMed ID: 33188139
[TBL] [Abstract][Full Text] [Related]
28. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
29. Immunophenotypic Analysis of CAR-T Cells.
de Azevedo JTC; Mizukami A; Moço PD; Malmegrim KCR
Methods Mol Biol; 2020; 2086():195-201. PubMed ID: 31707677
[TBL] [Abstract][Full Text] [Related]
30. CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models.
Li H; Ding J; Lu M; Liu H; Miao Y; Li L; Wang G; Zheng J; Pei D; Zhang Q
J Immunother; 2020 Jan; 43(1):16-28. PubMed ID: 31574023
[TBL] [Abstract][Full Text] [Related]
31. Effective Targeting of TAG72
Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
Front Immunol; 2018; 9():2268. PubMed ID: 30510550
[TBL] [Abstract][Full Text] [Related]
32. Improved survival of chimeric antigen receptor-engineered T (CAR-T) and tumor-specific T cells caused by anti-programmed cell death protein 1 single-chain variable fragment-producing CAR-T cells.
Nakajima M; Sakoda Y; Adachi K; Nagano H; Tamada K
Cancer Sci; 2019 Oct; 110(10):3079-3088. PubMed ID: 31432594
[TBL] [Abstract][Full Text] [Related]
33. Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo.
Liu G; Zhang Q; Liu G; Li D; Zhang L; Gu Z; Tian H; Zhang Y; Tian X
Exp Cell Res; 2021 Dec; 409(1):112886. PubMed ID: 34673000
[TBL] [Abstract][Full Text] [Related]
34. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
35. E-cadherin gene re-expression in chronic lymphocytic leukemia cells by HDAC inhibitors.
Jordaan G; Liao W; Sharma S
BMC Cancer; 2013 Feb; 13():88. PubMed ID: 23432814
[TBL] [Abstract][Full Text] [Related]
36. Analysis of CAR-Mediated Tonic Signaling.
Calderon H; Mamonkin M; Guedan S
Methods Mol Biol; 2020; 2086():223-236. PubMed ID: 31707680
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic strategies to boost CAR T cell therapy.
Akbari B; Ghahri-Saremi N; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
Mol Ther; 2021 Sep; 29(9):2640-2659. PubMed ID: 34365035
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism.
Huang Y; Shao M; Teng X; Si X; Wu L; Jiang P; Liu L; Cai B; Wang X; Han Y; Feng Y; Liu K; Zhang Z; Cui J; Zhang M; Hu Y; Qian P; Huang H
Cell Rep Med; 2024 Feb; 5(2):101400. PubMed ID: 38307031
[TBL] [Abstract][Full Text] [Related]
39. Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9.
Liu L; Bi E; Ma X; Xiong W; Qian J; Ye L; Su P; Wang Q; Xiao L; Yang M; Lu Y; Yi Q
Nat Commun; 2020 Nov; 11(1):5902. PubMed ID: 33214555
[TBL] [Abstract][Full Text] [Related]
40. PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells.
Zheng W; O'Hear CE; Alli R; Basham JH; Abdelsamed HA; Palmer LE; Jones LL; Youngblood B; Geiger TL
Leukemia; 2018 May; 32(5):1157-1167. PubMed ID: 29479065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]